REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO (Nasdaq: RGNX) has announced its participation in five major investor conferences during March and April 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) has announced its participation in five major investor conferences during March and April 2025. The company will engage in fireside chat presentations at:
- TD Cowen's 45th Annual Health Care Conference in Boston (March 5, 1:10pm ET)
- Leerink Partners Global Healthcare Conference in Miami (March 11, 9:20am ET)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 12, 3:30pm ET)
- UBS Virtual CNS Day (March 17, 10:00am ET)
- RBC Inaugural Virtual Ophthalmology Conference (April 3, 8:15am ET)
Select fireside chats will be available via live webcast through REGENXBIO's website, with recordings accessible for approximately 30 days after each presentation.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -0.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TD Cowen's 45th Annual Health Care Conference
Fireside Chat: Wednesday, March 5 at 1:10pm ET
Location:
Leerink Partners Global Healthcare Conference
Fireside Chat: Tuesday, March 11 at 9:20am ET
Location:
Barclays 27th Annual Global Healthcare Conference
Fireside Chat: Wednesday, March 12 at 3:30pm ET
Location:
UBS Virtual CNS Day
Fireside Chat: Monday, March 17 at 10:00am ET
Location: Virtual
RBC Inaugural Virtual Ophthalmology Conference
Fireside Chat: April 3 at 8:15am ET
Location: Virtual
Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302385213.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.